叔-丁基4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-羧酸酯 | 165947-52-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 叔-丁基4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-羧酸酯
• 英文名称: tert-butyl 4,7-dihydrothieno[2,3-c]pyridine-6(5H)-carboxylate
• 英文别名: 6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine；tert-butyl 4,5-Dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate；tert-butyl 5,7-dihydro-4H-thieno[2,3-c]pyridine-6-carboxylate
• CAS: 165947-52-4
• 化学式: C₁₂H₁₇NO₂S
• mdl: MFCD08752873
• 分子量: 239.338
• InChiKey: WSFBIDRTNUEVBV-UHFFFAOYSA-N

物化性质

• 沸点：
  339.1±42.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  叔-丁基4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-羧酸酯 在 四(三苯基膦)钯 、 溴 、 lithium perchlorate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 氯仿 、 水 、 乙腈 为溶剂， 反应 46.0h， 生成 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-3-yl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
  参考文献：
  名称：

  Design, Synthesis, and Structure–Activity Relationship Studies of Novel Fused Heterocycles-Linked Triazoles with Good Activity and Water Solubility

  摘要：

  Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4]-triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

  DOI：

  10.1021/jm4016284
• 作为产物：
  描述：

  3-氨乙基噻吩 在 sodium tetrahydroborate 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 9.0h， 生成 叔-丁基4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-羧酸酯
  参考文献：
  名称：

  Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

  摘要：

  KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

  DOI：

  10.1016/j.bmcl.2018.05.019

文献信息

• [EN] TRICYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES A BASE DE TYRAZOLES TRICYCLIQUES
  申请人：ABBOTT LAB

  公开号：WO2005095387A1

  公开（公告）日：2005-10-13

  Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  本发明的化合物对抑制蛋白酪氨酸激酶具有用处。还公开了制备这些化合物的方法、含有这些化合物的组合物以及使用这些化合物进行治疗的方法。
• Benzopiperidine derivatives
  申请人：Eisai Co., Ltd.

  公开号：US06518423B1

  公开（公告）日：2003-02-11

  Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

  本茨哌啶衍生物，由公式(I)表示，其盐或水合物，其制备方法以及包含其的药物: 其中变量如说明书中所述。这些化合物作为药物有效，用于预防和治疗这些各种炎症性疾病和免疫性疾病，如类风湿性关节炎、特应性皮炎、银屑病、哮喘和伴随器官移植的排斥反应。
• Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors
  作者：Hao-Yue Xiang、Jian-Yang Chen、Xia-Juan Huan、Yi Chen、Zhao-bing Gao、Jian Ding、Ze-Hong Miao、Chun-Hao Yang

  DOI：10.1016/j.bmcl.2020.127710

  日期：2021.1

  A library of new 2-substituted pyrrolo[1,2-b]pyridazine derivatives were rapidly assembled and identified as PARP inhibitors. Structure-activity relationship for this class of inhibitor resulted in the discovery of most potent compounds 15a and 15b that exhibited about 29- and 5- fold selective activity against PARP-1 over PARP-2 respectively. The antiproliferative activity of the as-prepared compounds

  一个新的 2-取代吡咯并[1,2- b ]哒嗪衍生物文库被快速组装并鉴定为 PARP 抑制剂。这类抑制剂的构效关系导致发现了最有效的化合物15a和15b，它们对 PARP-1 的选择性活性分别是 PARP-2 的 29 和 5 倍。通过在 BRCA2 缺陷型 V-C8 和 BRCA1 缺陷型 MDA-MB-436 细胞系中的进一步细胞测定证明了所制备化合物的抗增殖活性，表明化合物15b可以用 CC 50强力降低相应的细胞增殖和生长s 分别为 340 和 106 nM。15b的PK属性 这里也被调查了。
• Condensed compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05998433A1

  公开（公告）日：1999-12-07

  This invention provides new condensed furan compounds which exhibit excellent 2,3-oxidosqualene cyclase inhibition and high-density lipoprotein-cholesterol elevating activities. This invention also provides a therapeutic and prophylactic agent for hyperlipidemia, hypercholesterolemia and atherosclerosis.

  这项发明提供了新的浓缩呋喃化合物，表现出优异的2,3-氧化甾醇合酶抑制和高密度脂蛋白胆固醇升高活性。该发明还提供了一种治疗和预防高脂血症、高胆固醇血症和动脉粥样硬化的药物。
• 取代噁唑烷酮类化合物及其使用方法和用途
  申请人：广东东阳光药业有限公司

  公开号：CN104497008B

  公开（公告）日：2016-11-16

  本发明提供一种如式(I)所示的取代噁唑烷酮类化合物或其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药，用于抑制Xa因子。式(I)中为单键或是双键；K为6个原子组成杂环基或苯基；X为CR或N，其中R为H或卤素；R1为5个原子组成的杂芳基，所述5个原子组成的杂芳基任选地被卤素取代；L1为键、‑C(＝O)NHCH2‑或‑CH2NHC(＝O)‑；L2为‑C(＝O)NH‑或‑NHC(＝O)‑；和n为0或1。本发明还提供了包含该类化合物的药物组合物和使用本发明化合物或其药物组合物预防或治疗血栓栓塞性疾病的方法。